15
Apr 2026
MAIA: Bringing AI into your sample preparation
Transform laboratory workflows with MAIA, the AI agent offering instant expert guidance for microwave digestion, ensuring optimal sample preparation.
Stay Informed!
15
Apr 2026
Metabolic syndrome doubles worldwide over two decades
A global study reveals a sharp rise in metabolic syndrome prevalence from 2000 to 2023, highlighting urgent public health challenges and regional disparities.
15
Apr 2026
ORGAPRED selects CYTOQUBE® from Hamamatsu Photonics for personalized oncology research and therapeutic discovery
ORGAPRED, a France-based core facility specializing in Patient-Derived Tumor Organoid (PDTO) research, has selected the CYTOQUBE high-throughput 3D imaging system from Hamamatsu Photonics France to support personalized oncology drug screening and therapeutic discovery.
15
Apr 2026
Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa), nirsevimab (Beyfortus), and tremelimumab (Imjudo), and released a recombinant monoclonal anti-biotherapeutic antibody specific to dulaglutide (Trulicity).
15
Apr 2026
SPT Labtech and EMBL GeneCore collaborate to advance fully walkaway automation in genomics workflows
SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and the European Molecular Biology Laboratory's Genomics Core Facility (EMBL GeneCore), today announced a collaboration to advance fully walkaway automated genomics workflows.
15
Apr 2026
ProImmune collaborates with The University of Texas Medical Branch to advance infectious disease research
ProImmune, Ltd., a global leader in immunological reagents and services, today announced a collaboration with The University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL), a high-containment, infectious disease research facility, to develop innovative tools for studying high-consequence emerging and endemic infectious diseases.
15
Apr 2026
VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics
VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug discovery, today announced the formation of its Scientific Advisory Board (SAB), appointing John Lambert as Chair, with Morris Rosenberg and Peter de Waele serving alongside.
15
Apr 2026
ELRIG announces inaugural US drug discovery conference
ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the launch of Drug Discovery USA 2026.
15
Apr 2026
OBN rebrands to BioUK in alignment with its mission to
OBN (UK) Ltd., the not-for-profit membership organization focused on catalyzing success UK life sciences, today announced that it is changing its name to BioUK® .
14
Apr 2026
New biomarker predicts prognosis and treatment response in colorectal cancer
Determining the presence of a protein in non-tumor cells within the cancer microenvironment could be one of the keys to establishing prognosis in patients with colon and rectal cancer.
